chaitanyag11

Global vehicle electrification market was valued at US$ 57.50 billion in 2016, is projected to exhibit a CAGR of 8.82% over the forecast period (2017–2025), to be valued at US$ 121.60 billion by 2025. 

According to the U.S. Environmental Protection Agency (EPA), around 27% of the U.S. greenhouse gas emissions (GHG) is from the automotive sector. 

Electric Bicycles Market report presents the detail analysis of the parent market based on elite players, present, past and futuristic data which will serve as a profitable guide for all the industry competitors. Top players in the industry include Accell Group, Derby Cycle AG, Easy Motion, Jiangsu Xinri E-Vehicle Co. Ltd., Panasonic, Pedego, Stromer, and Yadea Technology Group Co. Ltd., BionX, Bosch, Electric Bike Technologies LLC, Giant Bicycles, GRACE, Superpedestrian, and Trek.

Global vehicle-to-everything (V2X) test equipment market is expected to witness a significant growth during the forecast period (2019–2027). The market growth for vehicle-to-everything (V2X) test equipment is majorly attributed to rising government initiatives for commercializing V2X technology and developing vehicle infrastructure to improve safety, performance, and environmental benefits. For Instance, In May 2019, the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) and Federal Motor Carrier Safety Administration (FMCSA) issued a notice to remove unnecessary regulatory barriers to the safe introduction of automated driving systems (ADS) vehicles in the United States. Furthermore, evolution of 5G technology is a major factor that is expected to drive the global vehicle-to-everything (V2X) test equipment market, before adopting it in the V2X technology.

Novel Drug Delivery System (NDDS) refers to the formulations, systems to transport pharmaceutical compound in the body, and approaches needed to achieve the desired therapeutic effect. The side effects and slow processing of conventional drug therapy are contributing to the emergence of novel drug delivery system’s concept. Novel ideas based on interdisciplinary approaches controlling the pharmacodynamics, immunogenicity, pharmacokinetics, bio-recognition, and efficiency of drugs were generated. This new system helps in reducing the drug degradation, increasing availability of drugs, and prevent from harmful side effects of drugs. This system provides various commercial and therapeutic benefits by enabling to formulate the novel drug delivery devices so that it can incorporate the drug molecules into the new delivery system.

Healthcare industry is rapidly adopting new technologies such as Artificial Intelligence (AI), robotics, medical imaging analytics; and extracting maximum benefits to drive down operational efficiencies, reduce cost of care, and enhance quality of care.

Specimen retrieval bags are used in the laparoscopic (abdomen and pelvic) surgical procedures. These bags temporarily contain biological materials such as adnexal cysts and masses and facilitate its removal from patient’s body. These bags are designed to reduce contamination of the abdominal cavity during surgeries. These tear-resistant high-quality bags are manufactured from nylon and coated by polyurethane. The specimen retrieval bag has an open end, closed end, and longitudinal axis for the collection of biological materials. It is a single use surgical instrument.

The global veterinary oncology market size was valued at US$ 401.8 million in 2018, and is expected to witness a CAGR of 10.9% over the forecast period (2019–2026).

Veterinary cancer therapies aim to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatments such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer. The ongoing research activities undertaken by researchers for the development of novel formulations and therapies is expected to accelerate the global veterinary oncology market growth. For instance, in 2015 researchers at the University of Veterinary Medicine Vienna are exploring the molecular basis of cancer progression in canine cell lines. The research states that the modern cancer therapy can be revolutionized with the introduction of targeted therapies.

Glycine is the simplest amino acid, which is colorless and sweet-tasting crystalline solid. It is insoluble in ethanol and ethyl ether whereas it is moderately soluble in acetone. It helps in healthy functioning of kidney and liver, as it is naturally available in abundance. Glycine find applications in food & beverages, cosmetics & personal care, pharmaceuticals, chemical intermediate, and others. In animal feed and pet food, it is used as an additive and is also used as sweetener and in protein drinks.

Market Dynamics

Rising demand for glycine from various end users is driving growth of the market. Growing processed food market is expected to increase demand for glycine, owing to rising demand for easy and ready to cook food and fast food. Moreover, new food concepts such as ‘free food’, ‘rush-hour foods’, and others is expected to drive demand for glycine in the near future. The global consumption of animal products such as meat, milk, and eggs is expected to increase due to rising demand for protein-rich food. This in turn will increase demand for glycine in the animal feed, thereby fueling growth of the glycine market.

Get PDF Brochure of This Business Report:

https://www.coherentmarketinsights.com/insight/request-pdf/2886

Glycine is widely used in cosmetic industry. Therefore, rising demand for cosmetic products due to change in the lifestyle of consumers will drive the glycine market growth. For instance, it has been estimated that in the U.S., over 30% of glycine is used as an additive in cosmetics and personal care products, mostly deodorants and antiperspirants.

Market Outlook

On the basis of region, the global glycine market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East and Africa. North America holds dominant position in the global glycine market, however, the region is witnessing stagnant growth since past few months due to the sluggish demand. High demand for packaged food and meat products makes the market in the U.S leading in this region. Asia Pacific is the fastest growing region in the global glycine market, owing to the presence of emerging economies such as India, Japan, China, Singapore, and South Korea. Europe is expected to witness a moderate growth in the global glycine market during the forecast period, owing to sluggish growth of the end users and economic slowdown.

Key Players

Some of the major players operating in the global glycine market include Evonik Industries, GEO Specialty Chemicals, Inc., Showa Dekno KK, and The Dow Chemical Company.

Click To Reading More On Glycine Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Glycine is the simplest amino acid, which is colorless and sweet-tasting crystalline solid. It is insoluble in ethanol and ethyl ether whereas it is moderately soluble in acetone. It helps in healthy functioning of kidney and liver, as it is naturally available in abundance. Glycine find applications in food & beverages, cosmetics & personal care, pharmaceuticals, chemical intermediate, and others. In animal feed and pet food, it is used as an additive and is also used as sweetener and in protein drinks.

Lyophilization of the sterile injectable is necessary to maintain the stability of some unstable bulk ingredients. Lyophilization provides longer shelf life, from two to five years, to the molecule. Lyophilization also enables easy transportation of bulk drugs. Moreover, lyophilized drugs can be stored at room temperature. Manufacturers such as BUCHI Labortechnik AG, SP Scientific, and West Pharmaceutical Services, Inc. are focusing on development of lyophilization process to enhance production capacity of lyophilized drug. Moreover, pharmaceutical companies are focusing on the development of highly advanced lyophilized drug delivery systems, in order to address or meet significant challenges such as multistep drug administration procedures, inconvenience administration of drugs through self-injection, risk of needlestick injuries, and others (lengthy dose preparation timings).

The global lyophilized drugs market is estimated to be valued at US$ 322.9 Billion in 2018, and is expected to witness a CAGR of 7.1% during the forecast period (2018–2026).

Request A Sample Copy:

http://bit.ly/332Uh25

Increasing regulatory approvals for wide range of lyophilized formulations for various disease conditions is expected to drive growth of lyophilized drugs market. For instance, in April 2014, GlaxoSmithKline plc received the U.S. Food and Drug Administration (FDA) approval for its Tanzeum (albiglutide lyophilized for injection), for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Moreover, in September 2014, the U.S. Food and Drug Administration (FDA) approved a new formulation of Abilify Maintena (aripiprazole) for extended-release injectable suspension, a pre-filled dual-chamber syringe, developed by Otsuka Pharmaceutical Development & Commercialization, Inc. The drug is indicated for the treatment of schizophrenia in adults and in maintenance monotherapy treatment of bipolar I disorder in adults.

Furthermore, increasing initiatives such as acquisitions by key players for advancement and distribution of anesthetics to various healthcare providing organizations is expected to significantly drive the lyophilized drugs market growth. For instance, in December 2018, North American Partners in Anesthesia (NAPA), a single-specialty anesthesia and perioperative management firm in the U.S., acquired certain assets of Aisthesis Partners in anesthesia care and its affiliated medical practices (‘Aisthesis’). Aisthesis provides its anesthesia services to 25 ambulatory surgical centers (ASCs), 3 hospitals, and 3 physician offices across four states in the U.S. and the District of Columbia. Thus, this initiative may contribute to increasing demand for the lyophilized anesthetics drug, which in turn is expected to show significant market growth.

Global Lyophilized Drugs Market - Restraints

The growth of the lyophilized drugs market can be hindered due to increasing number of product recalls for lyophilized drugs and packaging type. In January 2019, U.S. Food and Drug Administration issued a product recall notice for three lots of Vecuronium Bromide for Injection, 10 mg (lyophilized powder), and one lot of Vecuronium Bromide for Injection, 20 mg (lyophilized powder), developed by Sun Pharmaceutical Industries, Inc. The product has been recalled due to the presence of glass particulate in the product.

Get PDF Brochure of This Business Report:

http://bit.ly/332RLJr

Global Lyophilized Drugs Market- Regional Analysis

North America is expected to witness lucrative growth in the global lyophilized drugs market, owing to increasing prevalence of diseases in the U.S. Presence of major manufacturers such as Fresenius Kabi, Merck & Co. Inc., and Amneal Pharmaceutical who are extensively engaged in manufacturing of lyophilized injectable is contributing to growth of the North America Lyophilized Drugs Market. Moreover, increasing product approvals by regulatory authorities in North America is expected to bolster growth of North America Lyophilized Drugs Market. For instance, in December 2015, Aurobindo Pharma Limited received the U.S. FDA approval to manufacture and market Methylprednisolone Sodium Succinate Injection USP (lyophilized drug), 40 mg/vial, 125 mg/vial, 500 mg/vial, and 2 g/vial. Asia Pacific is also expected to drive growth of the global lyophilized drugs market, owing to initiatives by key players to expand their production facility, in order to manufacture lyophilized drugs in large scale. For instance, in July 2017, Alembic Pharmaceuticals, based in India, opened its new manufacturing facility in Panelav, Gujarat, India. The new site has manufacturing capacity of around 20 million vials of liquid injectable and lyophilized concentrations.

Europe is expected to experience growth owing to continuous advancements in lyophilization processes and increasing launches of lyophilized drugs. For instance, in April 2017, BÜCHI Labortechnik AG introduced the modular Lyovapor platform for freeze drying (lyophilization). The new product offers continuous sublimation.

Key players operating in the global lyophilized drugs market include Sanofi S.A, Merck & Co., Inc., Fresenius Kabi USA, LLC., Ciron Drugs & Pharmaceuticals Pvt Ltd., GlaxoSmithKline plc., Mylan NV., Pfizer, Inc., Amneal Pharmaceuticals LLC, Otsuka Holdings Co., Ltd.  (Otsuka Pharmaceutical Co., Ltd.), and BTG Plc.

Click To Reading More On Lyophilized Drugs Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

Lyophilization of the sterile injectable is necessary to maintain the stability of some unstable bulk ingredients. Lyophilization provides longer shelf life, from two to five years, to the molecule. Lyophilization also enables easy transportation of bulk drugs. Moreover, lyophilized drugs can be stored at room temperature. Manufacturers such as BUCHI Labortechnik AG, SP Scientific, and West Pharmaceutical Services, Inc. are focusing on development of lyophilization process to enhance production capacity of lyophilized drug. Moreover, pharmaceutical companies are focusing on the development of highly advanced lyophilized drug delivery systems, in order to address or meet significant challenges such as multistep drug administration procedures, inconvenience administration of drugs through self-injection, risk of needlestick injuries, and others (lengthy dose preparation timings).

Opioids are the class of drugs that include illicit drugs such as heroin, codeine, fentanyl, meperidine, methadone, morphine, hydrocodone, diphenoxylate, hydromorphone, methylphenidate, oxycodone, and oxymorphone. Opioids are prescribed for pain management and treatment of cough and diarrhea. According to the survey conducted by Center for Behavioral Health Statistics and Quality (CBHSQ), in 2015, out of 20.5 million around 2 million (10%) Americans of 12 years age or older, which had a substance use disorder were on pain relievers and around 591,000 were on heroin.

Crisis in the U.S. Opioids Market

According to the New York Times analysis of state data, in 2016, drug overuse led to death of 59,000 to 65,000 people in the U.S. Around two-third of these deaths were due to opioids overuse and the number is expected to increase. According to a survey of National Institute of Drug Abuse (NIDA), deaths due to the overdose prescription of opioid pain relievers have more than tripled in the past 20 years, escalating to 16,651 deaths in the U.S. in 2010. It can be concluded from the analysis of the data (data from the survey and New York Times data), that death due to opioids have more than doubled in the past six years.

In October 2016, the U.S. government declared opioids crisis as an emergency to increase awareness among the public about overuse of opioids. The crisis also restricts doctors and pharmacy stores from over-prescribing or overstocking opioids. Furthermore, the government has approached leading pharmacy chains, insurance companies, and others for cooperation against opioid crisis. For instance, Attorney General of over 35 states sent a letter to the America’s Health Insurance Plans, national association whose members provide coverage for health care and related services, urging its members to reconsider coverage policies that may be fueling the opioid crisis in October 2017. Such measures can ensure proper usage of opioids and favor the market players in the U.S.

The U.S. opioids market was valued at US$ 12,046.3 million in 2015 and is expected to witness a moderate CAGR of 5.2% during the forecast period (2016–2024).

Request A Sample Copy:

http://bit.ly/2Mp9Tar

According to the American Academy of Pain Medicine (AAPM), 2011, around 1.8 billion people suffered from chronic pain. Moreover, according to the National Institute of Health (NIH) estimates in 2015, one in 10 people in the U.S. suffered from chronic pain. Increasing prevalence of chronic pain is expected to result in high prescription of opioids pain relievers, which in turn is expected to fuel the market growth. Easy availability and favorable insurance policy are other major drivers for growth of the U.S. opioids market.

The analysis of Medicare prescription drug plans, which covers 35.7 million people in the second quarter of 2017, by ProPublica — an investigative journal and The New York Times — a leading U.S. newspaper, revealed that only one-third of the covered people had any access to other types of pain killer and less-risky opioids. This was attributed to low cost of opioids drugs. The scenario might change, however, due to strict monitoring from government and regulatory bodies. 

Cannabis as potential alternative for pain relief can be a threat to the U.S. opioids market

Cannabis could be the alternative therapy for opioids. Currently, medical marijuana is legal in 28 states and the District of Columbia even though it is illegal under federal law. According to a research published in Annals of Internal Medicine, in majority of cases, between 45% and 85%, medical marijuana is used for pain management. However, there is some ambiguity about medical marijuana effectiveness in pain management. Cannabis could be used as effective therapy after establishment of clinical trials. 

Some major players operating in the U.S. opioids market include Purdue Pharma L.P., Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceuticals Industries Limited, Mallinckrodt Pharmaceuticals, Egalet Corporation, Endo Pharmaceuticals plc, Allergan, plc, and Pfizer Inc.

Click To Reading More On U.S. Opioids Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

The U.S. opioids market was valued at US$ 12,046.3 million in 2015 and is expected to witness a moderate CAGR of 5.2% during the forecast period (2016–2024).

According to the New York Times analysis of state data, in 2016, drug overuse led to death of 59,000 to 65,000 people in the U.S. Around two-third of these deaths were due to opioids overuse and the number is expected to increase. According to a survey of National Institute of Drug Abuse (NIDA), deaths due to the overdose prescription of opioid pain relievers have more than tripled in the past 20 years, escalating to 16,651 deaths in the U.S. in 2010. It can be concluded from the analysis of the data (data from the survey and New York Times data), that death due to opioids have more than doubled in the past six years.

Although, the global batten disease treatment market is very scarce, few key players offering cell regeneration therapies and few other forms of medication include Seneb BioSciences, Inc., BioMarin Pharmaceuticals and ReGenX Biosciences LLC. The U.S. FDA has recently approved BioMarin’s first ever drug to treat batten disease known as Brineura in 2017.

For instance, a joint study between Baylor College of Medicine, Texas Children’s Hospital, and King’s College London have discovered a treatment that has helped to improve the neurological symptoms in the mouse model of juvenile batten disease.